跳至主要内容
临床试验/NCT00254241
NCT00254241已完成4 期

Safety and Efficacy of Seroquel in First Episode Schizophrenia

AstraZeneca1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2002年5月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
80
试验地点
1
主要终点
The proportion of patients developing clinically significant EPS at any point between baseline (day 1) and final assessment

研究概览

简要总结

To compare the safety, tolerability and efficacy of Seroquel and risperidone in first episode schizophrenia

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-35 years Meet ICD-10 criteria for schizophrenia No abnormaility on clinical examination No previous episode of psychosis No previous antipsychotics of any kind in last 3 months

排除标准

  • Have received a course of antipsychotics drug treatment prior to entry which may introduce risk factors or interfere with study procedures Have received anticholinergics within 10 days of baseline aseessment Have received mood stabilizers or anti depressants within 2 weeks

结局指标

主要结局

The proportion of patients developing clinically significant EPS at any point between baseline (day 1) and final assessment

次要结局

  • CGI severity of illness
  • CGI global improvement
  • PANSS total score and subscales)
  • Abnormal Involuntary Movement Scale (AIMS)
  • Dose of anti cholinergic medication
  • Serum prolactin levels
  • Proportion of patients discontinuing treatment due to reasons of lack of efficacy or adverse effects
  • Proportion of patients experiencing relapse.

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验